Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in the Treatment of Adult Lower Limb Spasticity

Next Previous
Trial Profile

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in the Treatment of Adult Lower Limb Spasticity

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum toxin B (Primary)
  • Indications Hemiplegia
  • Focus Registrational; Therapeutic Use
  • Sponsors Solstice Neurosciences; Supernus Pharmaceuticals

Most Recent Events

  • 31 May 2024 This trial has been completed in Czech Republic.
  • 12 May 2023 This trial has been discontinued in Hungary and Poland (End Date: 17 Feb 2023), according to European Clinical Trials Database record.
  • 03 Mar 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top